Tsumura Syouseiryuuto[19] : 42 sachets(for two weeks)

Product Overview/Feature

Tsumura Syouseiryuuto[19] : 42 sachets(for two weeks)

Sale Price：US$39.79

Warehouse	Japan1
Manufacturer	TSUMURA & CO.
Brand	TSUMURA & CO.
JAN Code	---
GS1	---
Ingredient Code	5200075
Shipping Schedule	about 3 weeks after payment

Description

Phlegm, nasal inflammation, allergic rhinitis, nasal congestion, bronchial asthma, mucus, cold, lacrimation, and allergic conjunctivitis due to allergic reactions.

Presentation

42 sachets

Feature

Active Ingredients

9.0 g(3sachets for 1day) of TSUMURA Shoseiryuto extract granules contains 5.0 g of a dried extract of the following mixed crude drugs.JP Pinellia Tuber 6.0 gJP Processed Ginger 3.0 gJP Glycyrrhiza 3.0 gJP Cinnamon Bark 3.0 gJP Schisandra Fruit 3.0 gJP Asiasarum Root 3.0 gJP Peony Root 3.0 gJP Ephedra Herb 3.0 g(JP: The Japanese Pharmacopoeia)

Effect/Efficacy

Watery sputum, watery nasal discharge, nasal obstruction, sneezing, stridor, coughing, lacrimation in the following diseases:Bronchitis, bronchial asthma, rhinitis, allergic rhinitis, allergic conjunctivitis, and common cold

Usage/Dosage

The usual adult dose is 9.0 g/day orally in 2 or 3 divided doses before or between meals. The dosage may be adjusted according to the patient's age and body weight, and symptoms.

Cautions

(1)When TJ-19 is used, the patient’s “SHO” (constitution/symptoms) should be taken into account. The patient’s progress should be carefully monitored, and if no 1ｲmprovement in symptoms/findings is observed, continuous treatment should be avoided.

(2)Since TJ-19 contains Glycyrrhiza, careful attention should be paid to the serum potassium level, blood pressure, etc., and if any abnormality is observed, administration should be discontinued.

3)When TJ-19 is co-administered with other Kampo-preparations (Japanese traditional herbal medi-cines), etc., attention should be paid to the duplication of the contained crude drugs.

Contraindication

Adverse Reactions
TJ-19　has not been investigated (drug use investigations, etc.)to determine the incidence of adverse reactions.
Therefore,the incidence of adverse reactions is not known.

1. Interstitial pneumonia: If fever, cough, dyspnea, abnormal pulmonary sound (fine crackle), etc. are observed, diministration of TJ-19 should be discontinued, and examinations such as X-ray should be　performed immediately and appropriate measures such as administration of adrenocortical hormones taken.Besides, the patient should be advised to is-continueTJ-19 immediately and to make contact with the physician in the event of fever, cough, dyspnea, etc.

2.Pseudoaldosteronism: Pseudoaldosteronism such as hypokalemia, increased blood pressure, retention of sodium/body fluid, edema,increased body weight, etc. may occur. The patient should be carefully mo-nitored (measurement of serum potassium level, etc.), and if any abnormality is observed, administration should be discontinued and appropriate measures
such as administration of potassium preparations should be taken.

3. Myopathy: Myopathy may occur as a result of hypokalemia. The patient should be carefully monitored,and if any abnormality such as weakness,　convulsion/paralysis of limbs,　etc. are observed, administration should be discontinued and appropriate measures such as administration of potassium preparations should be taken.

4.Hepatic dysfunction and jaundice: Hepatic dysfunction may occur. The patient should be carefully monitored for abnormal findings. Administration should be discontinued and appropriate therapeutic measures should be taken, if abnormalities are observed.

5. Use in the Elderly
Because elderly patients often have reduced physiological function, careful supervision and measures such as reducing the dose are recommended.

6.　Use during Pregnancy, Delivery or Lactation　
The safety of TJ-19 in pregnant women has not been established. Therefore, TJ-19 should be used in pregnant women, women who may possibly be pregnant only if the expected therapeutic benefits outweigh the possible risks associated with treatment.

7.　Pediatric Use
The safety of TJ-19 in children has not been established.
[Insufficient clinical data.]